Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology

Volumn 16, Issue 5, 2017, Pages 360-368

  Hess, David C ^a   Wechsler, Lawrence R ^b   Clark, Wayne M ^c   Savitz, Sean I ^d   Ford, Gary A ^e   Chiu, David ^f   Yavagal, Dileep R ^g   Uchino, Ken ^h   Liebeskind, David S ⁱ   Auchus, Alexander P ^j   Sen, Souvik ^k   Sila, Cathy A ^l   Vest, Jeffrey D ^m   Mays, Robert W ⁿ  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m Medpace ^*  (United States)

ⁿ ATHERSYS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BRAIN ISCHEMIA; BRAIN STEM; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; FOLLOW UP; HALITOSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPOTENT STEM CELL; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RISK ASSESSMENT; SAFETY; SECONDARY INFECTION; SPLENECTOMY; STEM CELL TRANSPLANTATION; UNITED KINGDOM; UNITED STATES; ADULT STEM CELL; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONVALESCENCE; MIDDLE AGED; PROCEDURES; STROKE; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ADULT STEM CELLS; AGED; BONE MARROW TRANSPLANTATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPOTENT STEM CELLS; RECOVERY OF FUNCTION; STROKE; TREATMENT OUTCOME;

EID: 85015622149     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30046-7     Document Type: Article

References (34)

1. 1 Emberson, J, Lees, KR, Lyden, P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
2. 2 Goyal, M, Menon, BK, van Zwam, WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387 (2016), 1723–1731.
3. 3 Janowski, M, Wagner, DC, Boltze, J, Stem cell-based tissue replacement after stroke: factual necessity or notorious fiction?. Stroke 46 (2015), 2354–2363.
4. 4 Savitz, SI, Cramer, SC, Wechsler, L, Consortium, S, Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke 45 (2014), 634–639.
5. 5 Savitz, SI, Chopp, M, Deans, R, et al. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke 42 (2011), 825–829.
6. 6 Kalladka, D, Sinden, J, Pollock, K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet 388 (2016), 787–796.
7. 7 Steinberg, GK, Kondziolka, D, Wechsler, LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke 47 (2016), 1817–1824.
8. 8 Offner, H, Vandenbark, AA, Hurn, PD, Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience 158 (2009), 1098–1111.
9. 9 Savitz, SI, Misra, V, Kasam, M, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 70 (2011), 59–69.
10. 10 Lee, JS, Hong, JM, Moon, GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 28 (2010), 1099–1106.
11. 11 Jiang, Y, Jahagirdar, BN, Reinhardt, RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002), 41–49.
12. 12 Jiang, Y, Vaessen, B, Lenvik, T, Blackstad, M, Reyes, M, Verfaillie, CM, Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 30 (2002), 896–904.
13. 13 Kovacsovics-Bankowski, M, Streeter, PR, Mauch, KA, et al. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol 255 (2009), 55–60.
14. 14 Boozer, S, Lehman, N, Lakshmipathy, U, et al. Global characterization and genomic stability of human multistem, a multipotent adult progenitor cell. J Stem Cells 4 (2009), 17–28.
15. 15 Roobrouck, VD, Clavel, C, Jacobs, SA, et al. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cellsreflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 29 (2011), 871–882.
16. 16 Burrows, GG, Van't Hof, W, Newell, LF, et al. Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis. Stem Cells Transl Med 2 (2013), 745–757.
17. 17 Fischer, UM, Harting, MT, Jimenez, F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 18 (2009), 683–692.
18. 18 Hess, DC, Sila, CA, Furlan, AJ, Wechsler, LR, Switzer, JA, Mays, RW, A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke 9 (2014), 381–386.
19. 19 Sehouli, J, Loddenkemper, C, Cornu, T, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 6 (2011), 236–246.
20. 20 Clark, WM, Wissman, S, Albers, GW, Jhamandas, JH, Madden, KP, Hamilton, S, Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282 (1999), 2019–2026.
21. 21 Hacke, W, Kaste, M, Bluhmki, E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 359 (2008), 1317–1329.
22. 22 Hacke, W, Kaste, M, Fieschi, C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995), 1017–1025.
23. 23 Hacke, W, Kaste, M, Fieschi, C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352 (1998), 1245–1251.
24. 24 Broderick, JP, Palesch, YY, Demchuk, AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368 (2013), 893–903.
25. 25 Kidwell, CS, Jahan, R, Gornbein, J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 368 (2013), 914–923.
26. 26 Offner, H, Subramanian, S, Parker, SM, Afentoulis, ME, Vandenbark, AA, Hurn, PD, Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 26 (2006), 654–665.
27. 27 Vahidy, FS, Parsha, KN, Rahbar, MH, et al. Acute splenic responses in patients with ischemic stroke and intracerebral hemorrhage. J Cerebral Blood Flow Metabolism 36 (2016), 1012–1021.
28. 28 Sahota, P, Vahidy, F, Nguyen, C, et al. Changes in spleen size in patients with acute ischemic stroke: a pilot observational study. IntJ Stroke 8 (2013), 60–67.
29. 29 Mays, RW, Borlongan, CV, Yasuhara, T, et al. Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. J Exp Stroke Transl Med 3 (2010), 34–46.
30. 30 Jellema, RK, Ophelders, DR, Zwanenburg, A, et al. Multipotent adult progenitor cells for hypoxic-ischemic injury in the preterm brain. J Neuroinflammation, 12, 2015, 241.
31. 31 Walker, PA, Shah, SK, Jimenez, F, et al. Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: preserving the blood brain barrier via an interaction with splenocytes. Exp Neurol 225 (2010), 341–352.
32. 32 Liesz, A, Hu, X, Kleinschnitz, C, Offner, H, Functional role of regulatory lymphocytes in stroke: facts and controversies. Stroke 46 (2015), 1422–1430.
33. 33 Liesz, A, Kleinschnitz, C, Regulatory T cells in post-stroke immune homeostasis. Transl Stroke Res 7 (2016), 313–321.
34. 34 Prasad, K, Sharma, A, Garg, A, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke 45 (2014), 3618–3624.